Search

Displaying results 2261 - 2270 of 4212 in total
  1. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent fo...

  2. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  3. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    [L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

  4. Drug

    PlasmaCord

    go.drugbank.com/drugs/DB16363
    Experimental

    PlasmaCord is platelet-poor plasma that is derived by fractionation from sterile umbilical cord and placental blood. … [L27581] It is developed by Cellpraxis and is currently being investigated against severe acute respiratory syndrome (SARS).

  5. Drug

    Picolinic acid

    go.drugbank.com/drugs/DB05483
    Experimental

    It acts as an anti-infective and immunomodulator and is produced in approximately 25-50 mg quantities by the body on a daily basis through the breakdown of tryptophan. … As a therapeutic agent, the molecule works by binding to zinc finger proteins (ZFPs) in a way that changes their structures and disrupts zinc binding, inhibiting function.

  6. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    Since July 2013, lipegfilgrastim is marketed by the EMA as Lonquex for subcutaneously injection, where it is administered once following cytotoxic chemotherapy for each chemotherapy cycle in adult patients

  7. Drug

    Ponazuril

    go.drugbank.com/drugs/DB11452
    ExperimentalVet approved

    Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.

  8. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    Most currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin. … For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed.

  9. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

  10. Drug

    Ibuzatrelvir

    go.drugbank.com/drugs/DB19451
    Investigational

    Ibuzatrelvir is under investigation in clinical trial NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized but